Could a weekly shot replace daily HIV pills? new trial hints at possibility

NCT ID NCT06061536

Completed Disease control Sponsor: Shanxi Kangbao Biological Product Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 2 trial tested a new drug called lipovirtide, given as a weekly or biweekly injection, along with daily oral HIV medications. The study enrolled 64 HIV-positive adults who had never taken antiviral drugs before. Researchers measured how many participants had undetectable virus levels after 169 days, aiming to find the best dose and check safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lipovirtide (a weekly or biweekly injection) combined with daily oral nucleoside drugs (3TC and TDF)
What this could lead to: If it works, this could offer a less frequent treatment option for HIV, reducing the burden of daily pills.
What could go wrong: This is a small, early Phase 2 study with only 64 participants. The results may not apply to everyone, and the best dose and safety profile are still being determined.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

Tianjin Second People's Hospital

Tianjin, Tianjin Municipality, 300000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.